Drugs moving into the clinic: 29

By Mike Nagle

- Last updated on GMT

The latest in a series of periodic roundups of drugs that have
moved from preclinical research into clinical testing via the
announcement of a Phase I trial or an application for a trial to
industry regulators.
Sponsor Name Indication Mechanism
MerLion Pharmaceuticals Finafloxacin Oncology & Anti-infectives & Vaccines - Helicobacter pylori antibiotic (linked to gastric ulceration and gastric cancer) pH activated antibiotic
Affibody Her-2 Affibody Oncology - breast cancer Antibody alternative that is tagged by a radionuclide and so can be used as targeted therapy or diagnostic - the latter being the case with this trial
Biotie & Roche undisclosed Inflammation Human Vascular Adhesion Protein-1 (VAP-1) monoclonal antibody
Pharmacopeia & Schering-Plough PS948115 respiratory disease undisclosed
VaxInnate Corporation M2e vaccine Anti-infectives & Vaccines - influenza Targets the M2 ectodomain (M2e) portion of the flu virus, which is inherent regardless of virus strain
University of Alberta dichloroacetate Oncology - glioblastoma Dichloroacetate (DCA) retores mitochondrial function, thus restoring apoptosis. Phase II trial approved by Health Canada, but no Phase I ever been done. Develpoed privately as moelcule can't be patented

Related topics: Preclinical Research

Related news

Show more